A common reporting framework can simplify administration without making the underlying risks identical. That tension runs through FDA's December 20, 2016 final rule for combination products. The regulated products bring together two or more types among drugs, devices and biological products. For businesses, the question was how to organize reporting without losing the distinctions that made the combination special. [2016-30485][E9-23519]

FDA's October 1, 2009 proposal described a baseline-plus-supplement approach: use the reporting requirements linked to the authorization application while preserving specified requirements tied to constituent parts. This was a design argument for consistency, not measured evidence of lower costs. The final rule and proposal are successive records of one regulatory process, rather than independent confirmations of a more efficient market. [2016-30485][E9-23519]

The final sharing provision also narrowed the path information should take. Constituent-part applicants must exchange received information about specified deaths, serious injuries or adverse experiences within five calendar days of receipt. FDA removed the alternative of sharing only with the agency for this purpose. That did not eliminate separate FDA reports or extend this duty to every supplier and every event. [2016-30485][E9-23519]

The economic distinction is between reducing an unnecessary route and removing a safety obligation. The documents support the former as agency reasoning, not a conclusion that fewer obligations always improve competition. Existing application-based duties followed the January 19, 2017 effective date; specified additional provisions, including section 4.103 sharing, received an 18-month compliance deferral. Neither publication nor that transition schedule demonstrates savings, new entry or successful preservation of safety signals. [2016-30485][E9-23519]

Source documents

  1. Postmarketing Safety Reporting for Combination Productshttps://www.govinfo.gov/content/pkg/FR-2016-12-20/html/2016-30485.htm
  2. Postmarketing Safety Reporting for Combination Productshttps://www.govinfo.gov/content/pkg/FR-2009-10-01/html/E9-23519.htm